Journal Club 2024-2025 Year to Date Articles |
September 5, 2024: Taye, Kondle |
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (TT) |
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer A Nonrandomized Controlled Trial (SK) |
October 29, 2024: Hulgan, Malinosky |
Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure Results From SOLOIST-WHF (DH) |
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma (HM) |
November 12, 2024: Plumber, Koneru |
Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes (AP) |
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis (SK) |
January 2, 2025: Shah, Azhar |
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (ZS) |
Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis in Vietnam (AA) |
January 14, 2025: Momin, Weinstein |
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk (AM) |
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma (KW) |
January 21, 2025: Gokani, Moore |
Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura (VG) |
Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis (CM) |
January 31, 2025: Nguyen, Bartley |
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (JN) |
Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections (BB) |
March 18, 2025: Lujan, Abdelwahab |
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (SL) |
Inebilizumab for Treatment of IgG4-Related Disease (RA) |
March 19, 2025: Saji, Denys |
A Multicenter Randomized Controlled Trial of Microbiome-Based Artificial Intelligence-Assisted Personalized Diet vs Low-Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet: A Novel Approach for the Management of Irritable Bowel Syndrome (AS) |
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (AD) |
March 31, 2025: Veeramachaneni, Rizvi |
90Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial (TV) |
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis (TR) |
April 23, 2025: Nagineni, Santiago |
Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer (LN) |
Ponsegromab for the Treatment of Cancer Cachexia (KS) |
June 12, 2025: Thiruma, Hoang |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|